| 5303 FACT SHEET |
|
A Phase 2b,Double-Blind,Placebo-Controlled,Exploratory randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment Naïve Patients Infected withR5-Tropic HIV-1(ACTG 5303)
|
Purpose of This Trial:
|
|
To determine if an investigational HIV treatment regimen containing darunavir, ritonavir, emtricitabine, and maraviroc results in less bone density loss compared to a regimen of darunavir, ritonavir, emtricitabine, and tenofovir.
|
You may be eligible if you are: |
- Are an HIV positive man or woman, age 18 or older
- Have never taken HIV medications
- Have an HIV viral load greater than 1,000
- Have a certain type of HIV called “R5” - based on trofile testing
- Do not have resistance to medications used in the study
- Agree to neuropsychological testing
- Do not have an active Hepatitis B infection
- Are not pregnant, breast feeding, or planning pregnancy
- Have not started any hormonal therapies in the last 6 months
- Have not started oral contraceptives within 3 months
- Weigh less than 300 pounds
- Have not broken a bone because your bones are weak
|
| Medications While On Study:
|
|
All study medications will be provided at no cost
|
| Length of Study: |
| About 48 weeks
|
Schedule of Study Appointments: |
Screening, Pre-Entry, Entry, and Weeks 4, 16, 24, 36 and 48. Dual-energy X-ray absorptiometry (DXA) scans will be performed at entry and weeks 48.
|
| Reimbursement: |
|
Clinical exams, lab tests, and DXAs are provided at no cost. You will receive $20 per visit starting at entry, $25 for each DXA, and $10 for each neuropsychological test.
|
Contact: |
The ACTU Screening Nurse at 206-744-3184.
|
